Logo

Precision Biosciences Receives $3M to Further Develop Genetic Engineering Technology

Dec 17, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision Biosciences today said it has been awarded four government grants totaling more than $3 million for further development of its genome engineering technology.

The grants are from the National Institute of Standards and Technology, the US Department of the Treasury, the National Institutes of Health, and the state of North Carolina.

In a statement, Michael Nicholson, director of cell biology at the Durham, N.C., company said Precision Bio is ready to use its Directed Nuclease Editor technology to "address major challenges facing the biomanufacturing industry," and the funds will allow it to refine applications for the technology, in particular applications for cell line engineering.

Using custom-made DNA-cutting enzymes, Precision Bio changes the genetic sequence of a natural genome editing meganuclease to create a custome meganuclease with DNA-recognition and cleavage properties.

Filed under

NIST
NIH
gene editing
Precision Biosciences
Breaking News
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.